Read Our Blog

Call Us: (913) 544-1199

Tech in the City

Amanda Stevenson-Grund - Monday, May 21, 2018

Prof. Heike Mayer examined the emergence of so-called "second-tier" high-technology regions in the United States. These emerging high-technology regions are challenging traditional technology corridors such as Silicon Valley and Boston's Route 128.Heike Mayer. Spinoff Regions. Accessed March 11, 2018.

The plaza in Kansas City

“Everything’s up to date in Kanas City. They’ve gone about as far as they can go,” go the lyrics to Roger and Hammerstein’s song, “Kansas City.” The sentiment still holds true, especially as it pertains to Kansas City’s place in the tech world. Although not as populated as Silicon Valley, Kansas City is a budding tech hub that has seen great growth of its biotechnology, pharmaceutical and manufacturing industry.

 More >

From Delivery to Your Stomach to Your Intestines, Enteric Coating Can Help

Amanda Stevenson-Grund - Friday, May 04, 2018

Enteric coating is a useful strategy for the oral delivery of drugs like insulin which rapidly degrade in the stomach, as it prevents the drug being released in the acidic conditions of the stomach before reaching the intestine.Sonia and Sharma, Oral Delivery of Insulin. 2014; 113-168

Person clutches stomach

Enteric coating is ideal for protecting the active ingredients utilized in the treatment of some gastrointestinal (GI) disorders. Enteric coating is also useful in delivering treatment to other locations. Specifically, enteric coating is useful in the delivery of proteins and peptides, antibiotics and NSAIDS to the stomach and intestines.

 More >

From the Mouths of Babes: Solubility in Pediatric Oral Drugs

Amanda Stevenson-Grund - Friday, April 20, 2018

Compound solubility serves as a surrogate indicator of oral biopharmaceutical performance. Between infancy and adulthood, marked compositional changes in gastrointestinal (GI) fluids occur.” – Maharaj, et al. Pharm Res. 2016; 33: 52-71

Child swallows oral pediatric medication

Solubility is an important aspect in the development of oral drugs. It is especially important for developers to take into consideration during the development of oral pediatric drugs. Poorly soluble oral pediatric drugs can cause local tissue injury, reduced bioavailability and adverse events.

 More >

No Sugar-coating Needed: GI Disorders Need Enteric Coating

Amanda Stevenson-Grund - Friday, April 06, 2018

Enteric coatings are used to reduce gastrointestinal side effects and control the release properties of oral medications.” – Niwa, et al. Pharm Res. 2014; 31: 2140

This image represents the need for enteric coating.

There are many drug-delivery techniques, and each one has its strengths. One technique is enteric coating. Enteric coating is best for use with active ingredients that treat gastrointestinal (GI) disorders, such as ulcerative colitis, Crohn’s disease and irritable bowel syndrome.

 More >

Drug Delivery to the Small Intestine Can Lead to Big Results

Amanda Stevenson-Grund - Friday, March 23, 2018

The small intestine is the most common target site due to shortest transit time and a large surface area of specialized cells, microvilli, and associated microvessels for material absorption and transportation to the bloodstream.” – Sharpe, et al. Expert Opin Drug Deliv. 2014 Jun; 11(6): 901–915

A human's intestine

Small can be mighty, and the results of drug delivery to the small intestine give credence to this idea. There are many benefits of delivering drugs to the small intestine, including high surface area, ability to target drug delivery and short transit time.

 More >

Orbis Biosciences and Daré Bioscience Collaborate to Advance Innovation for Women's Reproductive Health!

Amanda Stevenson-Grund - Monday, March 12, 2018

Dare Bioscience logo

LENEXA, KS – March 12, 2018 –

Orbis Biosciences, Inc. announced today it has granted Daré Bioscience, Inc. an exclusive option to license worldwide rights to Orbis’ long-acting contraceptive products.  This agreement leverages Orbis’ StratµmTM technology to create an etonogestrel contraceptive for 6- and 12-month durations.  The agreement includes pre-clinical studies and the option to enter into a license agreement for clinical development.  Financial terms were not disclosed. 

 More >

Enteric Drug Delivery Coating Techniques

Amanda Stevenson-Grund - Friday, March 09, 2018

Enteric-coated products are designed to remain intact in the acidic juices of the stomach and then to release the drug at the higher pH of the small intestine (above pH 5.5) or at the even higher pH in the colon (above pH 6.5): the drug effectiveness would be reduced by stomach acids and enzymes if left unprotected.” – Dalmoro et al., AAPS PharmSciTech. 2010 Dec; 11: 1500–1507

An image represents enteric drug delivery

A common issue with active pharmaceutical ingredients (APIs) is their inability to withstand the harsh environment of the stomach acids. Enteric coating saves the API from being harmed by the gastric environment. This paramount step in creating a viable final product often takes multiple steps to achieve. 

 More >

Poorly Soluble Drugs: The New Norm?

Amanda Stevenson-Grund - Thursday, February 22, 2018

An estimated 40% of approved drugs and nearly 90% of the developmental pipeline drugs consist of poorly soluble molecules. Several marketed drugs suffer from poor solubility.” – Kalepu and Nekkanti, Acta Pharmaceutica Sinica B. 2015; 5: 442

Circles represent drugs with improved solubility

Poor solubility affects the ability of a drug to be absorbed by the body, limiting the amount of drug available to create the intended action on the body. In the Biopharmaceutics Classification System (BCS), classes II and IV include poorly soluble drugs. According to a 2013 review article in the Journal of Developing Drugs, 38 percent of the top 200 oral drugs in the U.S. fall into BCS classes II and IV. Parenteral drugs also run into issues with solubility and overall, around 40 percent of all New Chemical Entities (NCEs) have poor solubility. For NCEs, poor solubility can result in drug development failure. Although this issue may seem insurmountable, there are techniques to improve solubility through the drug product or drug product intermediate’s formulation.

 More >

Multiparticulate Dosage Forms Reduce Dose Dumping, Limiting Adverse Events

Amanda Stevenson-Grund - Friday, February 02, 2018

Multi-particulate dosage forms have several therapeutic and technological advantages over single-unit dosage forms, they can distribute evenly in the gastrointestinal tract, resulting in fewer adverse effects.” - Martínez-Terán et al. Pediatr Ther. 2017; 7:314

 A person clutches his or her stomach, representing adverse events

Even the best medications can have negative effects that affect a patient’s quality of life. However, your drug product’s format can positively affect the adverse event profile decreasing adverse events.

 More >

Orbis Biosciences Announces Licensing Agreement with Reckitt Benckiser

Amanda Stevenson-Grund - Tuesday, January 02, 2018

Orbis Biosciences logo

Orbis Biosciences, Inc. announced today that it has entered into an exclusive global license agreement leveraging its Precision Particle Fabrication® technology. Reckitt Benckiser (RB), world-leading Consumer Healthcare company, and Orbis have entered into an exclusive cooperation agreement to develop and commercialize novel technologies in the field of consumer healthcare. The technology will enable new products for a leading segment of RB's product portfolio. Detailed financial terms were not disclosed.

 More >